• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xoma Royalty Corporation (NQ: XOMA )

    31.10 +0.24 (+0.78%)
    Streaming Delayed Price Updated: 3:39 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Xoma Royalty Corporation

    < Previous 1 2 3 Next >
    XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
    Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
    From XOMA Corporation
    Via GlobeNewswire
    FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
    FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA's Return On Capital Employed Insights
    Via Benzinga
    XOMA Earnings Perspective: Return On Capital Employed
    Via Benzinga
    XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Announces Stock Repurchase Program of up to $50 Million
    Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
    From XOMA Corporation
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Monday
      During Monday, 102 stocks hit new 52-week lows. 
    Via Benzinga
    XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
    From XOMA Corporation
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Friday
      On Friday, 57 companies reached new 52-week lows. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
      During Thursday, 56 stocks hit new 52-week lows. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Wednesday
      Wednesday saw 59 companies set new 52-week lows. 
    Via Benzinga
    XOMA Added to the Russell 2000® and Russell 3000® Indexes
    From XOMA Corporation
    Via GlobeNewswire
    Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst
    Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and... 
    Via Benzinga
    XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
    New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹ 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    Recap: XOMA Q1 Earnings
    XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
    Via Benzinga
    XOMA: Q1 Earnings Insights
    XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
    Via Benzinga
    XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at H.C. Wainwright BioConnect Investor Conference
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
    Acquired IXINITY® commercial payment and milestone economics from Aptevo Therapeutics 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at 43rd Annual Cowen Health Care Conference
    From XOMA Corporation
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.